Results 91 to 100 of about 128,118 (293)

Data‐driven discovery of gene expression markers distinguishing pediatric acute lymphoblastic leukemia subtypes

Molecular Oncology, Volume 19, Issue 12, Page 3548-3577, December 2025.
This study investigates gene expression differences between two major pediatric acute lymphoblastic leukemia (ALL) subtypes, B‐cell precursor ALL, and T‐cell ALL, using a data‐driven approach consisting of biostatistics and machine learning methods. Following analysis of a discovery dataset, we find a set of 14 expression markers differentiating the ...
Mona Nourbakhsh, Nikola Tom, Anna Schrøder Lassen, Helene Brasch Lind Petersen, Ulrik Kristoffer Stoltze, Karin Wadt, Kjeld Schmiegelow, Matteo Tiberti, Elena Papaleo   +8 more
wiley   +1 more source

A study on the cytomorphologic structure of blood cells by vital staining II. Leukemic cells in the bone marrow [PDF]

, 1960
Leukemic cells were cytologically studied in the human bone marrow culture by the utilization of vital staining of Janus green B and neutral red. The minute cellular morphology of various types of leukemia was studied with special reference to their ...
Ota, Zensuke
core   +1 more source

The BCR-ABLT315I mutation compromises survival in chronic phase chronic myelogenous leukemia patients resistant to tyrosine kinase inhibitors, in a matched pair analysis

Haematologica, 2013
The BCR-ABL T315I mutation confers resistance to currently licensed tyrosine kinase inhibitors in chronic myelogenous leukemia. However, the impact of this mutation on survival in early stages of disease, in chronic phase, has never been detailed.
Franck E. Nicolini, Amr R. Ibrahim, Simona Soverini, Giovanni Martinelli, Martin C. Müller, Andreas Hochhaus, Inge H. Dufva, Dong-Wook Kim, Jorge Cortes, Michael J. Mauro, Charles Chuah, Hélène Labussière, Stéphane Morisset, Catherine Roche-Lestienne, Eric Lippert, Sandrine Hayette, Senaka Peter, Wei Zhou, Véronique Maguer-Satta, Mauricette Michallet, John Goldman, Jane F. Apperley, François-Xavier Mahon, David Marin, Gabriel Etienne   +24 more
doaj   +1 more source

mRNA Cancer Vaccines: From Pandemic Paradigm to Personalized Oncology Therapeutics

Cancer Innovation, Volume 4, Issue 6, December 2025.
This review highlights the transformative potential of mRNA cancer vaccines, leveraging technological advancements in nucleotide modification, lipid nanoparticle delivery, and AI‐driven neoantigen selection to enhance vaccine stability, immunogenicity, and personalization.
Bo Yang, Juan Liu, Yang Li, Xiaoxuan Liu
wiley   +1 more source

The polo-like kinase 1 (PLK1) inhibitor NMS-P937 is effective in a new model of disseminated primary CD56+ acute monoblastic leukaemia [PDF]

, 2013
CD56 is expressed in 15–20% of acute myeloid leukaemias (AML) and is associated with extramedullary diffusion, multidrug resistance and poor prognosis.
A Blair, A Cesano, A Vilas-Zornoza, AG Renner, Alessandro Rambaldi, Alessia Casolaro, Alice Pezzoni, B Löwenberg, B Valsasina, Barbara Valsasina, C McInnes, Clara Albanese, D Raspadori, E Di Bona, E Estey, E Radaelli, EM Lee, Enrico Pesenti, F Ravandi, FR Appelbaum, Francesco Bertolini, Francesco Marchesi, G Tsykunova, Gemma Texido, Gianni Cazzaniga, H Chang, I Beria, J Delgado, J Golay, J Suela, J Zuber, Josee Golay, JR Novontny, JW Rocco, K Strebhardt, M Bardini, Marco Losa, Martino Introna, MJ Walter, MR Baer, Nadia Amboldi, PA Greif, R Giavazzi, Rachele Alzani, Roberta Ceruti, S Gattenloehner, Sabrina Cribioli, Silvia Bungaro, T Berg, T Ikezoe, T Lapidot, TJ Ley, U Cucchi, Ursula Giussani, Veronica Patton, Z Li   +55 more
core   +3 more sources

Potential of Bacillus subtilis lipopeptides in anti-cancer I: induction of apoptosis and paraptosis and inhibition of autophagy in K562 cells

AMB Express, 2018
The lipopeptide iturin from Bacillus subtilis has been found to have a potential inhibitory effect on breast cancer, alveolar adenocarcinoma, renal carcinoma, and colon adenocarcinoma. In this study, the potential of B.
Haobin Zhao, Lu Yan, Xiaoguang Xu, Chunmei Jiang, Junling Shi, Yawen Zhang, Li Liu, Shuzhen Lei, Dongyan Shao, Qingsheng Huang   +9 more
doaj   +1 more source

RNA trafficking by acute myelogenous leukemia exosomes.

Cancer Research, 2013
Extrinsic signaling cues in the microenvironment of acute myelogenous leukemia (AML) contribute to disease progression and therapy resistance. Yet, it remains unknown how the bone marrow niche in which AML arises is subverted to support leukemic ...
Jianya Huan, N. Hornick, M. Shurtleff, Amy M. Skinner, Natalya A. Goloviznina, C. Roberts, P. Kurre   +6 more
semanticscholar   +1 more source

A Phase II Pilot Study of Anti‐PD‐L1, Durvalumab, and a PARP Inhibitor, Olaparib in Patients With Metastatic Triple‐Negative Breast Cancer With or Without Germline BRCA Mutation

Cancer Medicine, Volume 14, Issue 23, December 2025.
ABSTRACT Background Immunostimulatory effects of PARP inhibitors could increase sensitivity to immune checkpoint inhibitors. The previous Phase II trial (MEDIOLA) reported clinical benefits of durvalumab and olaparib (D + O) in patients with germline BRCA‐mutated (gBRCAm) HER2‐negative metastatic breast cancer.
Takeo Fujii, Ashley Cimino‐Mathews, Stanley Lipkowitz, Min‐Jung Lee, Jayakumar Nair, Britanny Brooke Solarz, Alexandra Zimmer, Bernadette Redd, Elliot B. Levy, Shraddha Rastogi, Nahoko Sato, Ann McCoy, Seth M. Steinberg, Jung‐Min Lee   +13 more
wiley   +1 more source

The detection and classification of blast cell in Leukaemia Acute Promyelocytic Leukaemia (AML M3) blood using simulated annealing and neural networks [PDF]

, 2011
This paper was delivered at AIME 2011: 13th Conference on Artifical Intelligence in Medicine.This paper presents a method for the detection and classification of blast cells in M3 with others sub-types using simulated annealing and neural networks.
Hassan, R, Ismail, W, Payne, A, Swift, S
core  

A long-lasting, complete hematologic and cytogenetic remission of chronic myelogenous leukemia after treatment with busulfan alone [PDF]

, 1996
A 44-year-old man suffering from cytogenetically and molecularly proven Philadelphia translocation-positive chronic myelogenous leukemia in chronic phase was treated with busulfan for 18 months and studied during a follow-up period of 13 years ...
Geurts van Kessel, A.H.M. (Ad), Haanen, C. (C.), Hagemeÿer, A. (A.), Mandigers, C., Mensink, E.J.B.M. (Ewald), Plas, D. (D.) van der, Witte, T. de   +6 more
core   +1 more source